Allergan, Inc. v. Apotex, Inc. (Fed. Cir.)

by Robins Kaplan LLP
Contact

Case Name: Allergan, Inc. v. Apotex, Inc., No. 2013-1245, -1246, -1247, 2014 U.S. App. LEXIS 10710 (Fed. Cir. June 10, 2014) (Circuit Judges Prost, Reyna and Chen presiding; Opinion by Prost, C.J.; Dissent-in-part by Chen, J.) (Appeal from M.D.N.C., Eagles, J.)

Drug Product and Patent(s)-in-Suit: Latisse® (bimatoprost ophthalmic solution); U.S. Patents Nos. 7,388,029 (“the ’029 patent”) and 7,351,404 (“the ’404 patent”)

Nature of the Case and Issue(s) Presented: By the mid-1980s, it was established that naturally occurring prostaglandin analogues (PGF) could alleviate intraocular pressure (IOP), which is associated with the eye disease glaucoma. Bimatoprost is a PGF that received FDA approval in 2001—and marketed as Lumigan®--as an eye drop to treat glaucoma. Hair loss treatment was another area in which certain PGFs proved useful. One such PGF, latanoprost, also received FDA approval for use in glaucoma treatment. The formulator that studied latanoprost, Dr. Johnstone, filed a patent application on the use of latanoprost and other PGFs to promote hair growth in February 1997.

Defendants appeal from a final judgment of the district court finding the patents-in-suit valid and infringed. The Federal Circuit reversed the district court’s findings with respect to the validity of each patent.

Why Defendants Prevailed: The issue of infringement hinged on the district court’s construction of the claim term “treating hair loss” in the ‘’029 patent. All parties, as well as the district court, agreed that the specification provides an express definition for the term: “’Treating hair loss’ includes arresting hair loss or reversing hair loss, or both, and promoting hair growth.” Defendants argue that use of “and” in the lexicographic definition provides that the method for treating hair loss must both arrest or reverse hair loss, as well as also promote hair growth. Under that view, defendants’ generic Latisse would not infringe because Latisse only promotes hair growth. The district court agreed with Allergan that the use of the word “includes” in the lexicographic definition plainly means that the patentee intended to define treating hair loss to include the possibility of one or all of arresting hair loss, reversing hair loss, or promoting hair growth. This is evidenced by the various examples in the patent that illustrate all three types of treatment. Because there is nothing in either the specification or the claims suggesting that the patentee would have excluded these examples from the scope of the claimed methods, the Federal Circuit affirmed the district court’s construction and finding of infringement.

Next, defendants assert that the ’029 patent is invalid as anticipated by (i) Dr. Johnstone’s patent publication concerning the use of latanoprost to promote hair growth; and (ii) an earlier Allergan patent on the use of bimatoprost  to treat glaucoma. The Federal Circuit did not agree because the Johnstone application expressly discloses PGF structures in which the alpha chain includes a double bond. The ’029 claims expressly exclude such a structure. With respect to Allergan’s prior-art patent, it did not refer to hair growth or treating hair loss, nor did it disclose topical application of any compounds. At issue, therefore, was whether promoting hair growth through topical application of bimatoprost on the skin is necessarily present or inherent in the method of applying eyedrops containing bimatoprost. Because the district court’s findings—that it was at least possible to administer eyedrops in a way as to reduce the flow of liquid to the eye to close to zero and there was no express teaching in the prior-art patent that described how fluid from the eye drop could transfer to the skin—were not clearly erroneous, the Federal Circuit affirmed.

The district court had found that the ’029 patent was not obvious because there was no motivation to combine the Johnstone application with Allergan’s prior-art patent due to “pharmacological differences” between the compounds that each reference discloses. Here, the Federal Circuit disagreed. “The district court reached its conclusions of non-obviousness by looking only at properties of the C1-amide group and, particularly, bimatoprost. In doing so, the district court erred by failing to take into account the full scope of the ’029 patent claims.” The Federal Circuit also said that the district court took an “overly cramped view” of what the prior art taught and found that the Johnstone application did suggest the possibility of using a PGS structure that would include a single bond, merely without adequate explanation within the reference itself. The Federal Circuit further found that the district court’s findings on secondary considerations “suffer from the same infirmity of lacking a nexus with the scope of the ’029 patent’s claimed invention.” The finding of non-obviousness was therefore reversed.

The ’404 patent obviousness analysis concerned four references known as the Brandt references, and whether they would render the ’404 patent obvious in light of the Johnstone application. The Brandt references were published clinical trials that allegedly disclose the ability of bimatoprost to promote eyelash hair growth. The first two Brandt references are indisputably prior art. Those references do not, however, expressly refer to bimatoprost. With respect to the other two Brandt references, the district court found that the ’404 patent was invented prior to their publication date and therefore, those references were not prior art. The Federal Circuit reversed the district court’s finding that the ‘’404 patent pre-dated any of the Brandt references. It held that the district court committed clear error in finding corroboration of an earlier priority date in documents that collectively did not include any description of the claimed invention of the ’404 patent, and in relying on corroborating evidence of conception from the self-serving oral testimony of a co-inventor. In light of the Brandt references’ disclosure of bimatoprost’s effect in growing eyelash hair, a skilled artisan would have had substantial motivation to follow Johnstone’s application and use topical application of bimatoprost to grow eyelash hair. The asserted claims of the ’404 patent were therefore also obvious.

In partial dissent, Judge Chen would not have found the ’029 patent obvious by the Johnstone application, either alone or in combination with the Allergan prior-art patent. In his view, “Johnstone’s teaching are simply too vague and equivocal to justify invalidating the patent.” Judge Chen stressed the presumption of validity of an issued patent and also noted that the Patent Office considered the Johnstone application during the prosecution of the ’029 patent application and found that it did not render the claims obvious.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Robins Kaplan LLP | Attorney Advertising

Written by:

Robins Kaplan LLP
Contact
more
less

Robins Kaplan LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.